Table 2.
Treatment outcomes.
| MLTD group (n = 13) | Control group (n = 13) | P value | |
|---|---|---|---|
| MDZ dose, mg (IQR) | 3 (3–4) | 2.5 (2–4) | 0.62 |
| MucoUp dose, mL (IQR) | 28 (15–40) | 20 (16–40) | 0.64 |
| Maneuverability, n (%) | 0.4 | ||
| Good/normal | 10 (76.9) | 8 (61.5) | |
| Poor | 3 (23.1) | 5 (38.5) | |
| Poor submucosal lifting because of fibrosis, n (%) | 1.0 | ||
| Positive | 0 (0) | 0 (0) | |
| Procedure time, min (IQR) | 50 (33–63) | 30 (23–55) | 0.38 |
| Dissection speed, mm2/min (IQR) | 19.9 (14.4–26) | 28.7 (17–35.7) | 0.19 |
| Specimen damage, n (%) | 1.0 | ||
| Yes | 0 (0) | 1 (7.7) | |
| En bloc resection, n (%) | 1.0 | ||
| Yes | 100 (13) | 100 (13) | |
| Resectabillity, n (%) | 1.0 | ||
| R0 | 100 (13) | 100 (13) | |
| Resected tumor size, mm (IQR) | 30 (22–33) | 24 (20–36) | 0.92 |
| Largest diameter of the resected specimen, mm (IQR) | 43 (32–45) | 34 (30–45) | 0.74 |
| Smallest diameter of the resected specimen, mm (IQR) | 30 (22–33) | 33 (24–38) | 0.61 |
| Final pathology, n (%) | |||
| Histology | 0.12 | ||
| Adenoma | 9 (69.2) | 5 (38.5) | |
| Tub | 4 (30.8) | 8 (61.5) | |
| Por, sig, muc | 0 (0) | 0 (0) | |
| Depth | 0.29 | ||
| Tis | 3 (23.1) | 6 (46.2) | |
| T1a | 1 (7.7) | 2 (15.4) | |
| T1b | 0 (0) | 0 (0) | |
| Intraoperative perforation, n (%) | 1.0 | ||
| Yes | 0 (0) | 0 (0) | |
| Intraoperative bleeding, n (%) | 1.0 | ||
| Yes | 0 (0) | 0 (0) | |
| Delayed perforation, n (%) | 1.0 | ||
| Yes | 0 (0) | 0 (0) | |
| Delayed bleeding, n (%) | 1.0 | ||
| Yes | 0 (0) | 0 (0) | |
| Surgery due to adverse events, n (%) | 1.0 | ||
| Yes | 0 (0) | 0 (0) | |
| Recurrence, n (%) | 1.0 | ||
| Yes | 0 (0) | 0 (0) | |
IQR interquartile range, MZD midazolam.